期刊文献+

不同剂量辛伐他汀治疗老年冠心病78例观察 被引量:3

原文传递
导出
摘要 目的观察不同剂量辛伐他汀治疗老年冠心病的效果。方法将78例老年冠心病患者随机分为观察组和对照组,治疗组39例患者每晚服用40mg辛伐他汀,对照组39例患者每晚服用20mg辛伐他汀,观察两组治疗前后血脂、肝功能、肾功能等指标变化情况。结果每天服用40mg辛伐他汀可以显著降低总胆固醇(TC)、三酰甘油(TG)和低密度脂蛋白(LDL)水平,升高高密度脂蛋白(HDL)水平。结论对于老年冠心病患者,每天服用辛伐他汀40mg是较安全的调脂剂量,可达到理想调脂水平。
出处 《中国基层医药》 CAS 2010年第17期2394-2395,共2页 Chinese Journal of Primary Medicine and Pharmacy
  • 相关文献

参考文献13

  • 1陈灏珠.内科学.4版.北京:人民卫生出版社,1997,274
  • 2Danchin N.C-reactive protein for risk assessment in coronary artery disease.Heart,2010(96):325-327.
  • 3Yang X,Sheng W,He Y,et al.Secretory phospholipase A2 type Ⅲ enhances(alpha)-secretase-dependent amyloid precursor protein processing through alterations in membrane fluidity J.Lipid Res.2010,51 (5):957-966.
  • 4沈干.血脂异常及治疗若干进展[J].中国临床保健杂志,2004,7(1):68-71. 被引量:15
  • 5Downs JR,Beere PA,Whitney E,et al.Design& rationale of the AirForce/Texas Coronary Atherosclerosis Prevention Study (AF-CAPS/Tex-CAPS).Am JCardio,1 1997,80(3):287-293.
  • 6Taylor AJ,Villines TC,Stanek EJ,et al.Extended-Release Niacin or Ezetimibe and Carotid Intima-Media Thickness.NEJM,2009(361):2113-2122.
  • 7马立宁,江宁,张丽.辛伐他汀在急性冠脉综合征中的应用[J].中国临床保健杂志,2005,8(2):129-130. 被引量:2
  • 8Eldor R,Raz I.American Diabetes Association Indications for Statins in Diabetes:Is there evidence.Diabetes Care,2009 (32):S384-S391.
  • 9MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals:a randomised placebo-controlled trial.Lancet,2002,360(9374):7-22.
  • 10Zulli,A,Lau,E,Wijaya,B.P,et al.High Dietary Taurine Reduces Apoptosis and Atherosclerosis in the Left Main Coronary Artery:Association With Reduced CCAAT/Enhancer Binding Protein Homologous Protein and Total Plasma Homocysteine but not Lipidemia.Hypertension,2009(53):1017-1022.

二级参考文献26

共引文献27

同被引文献33

  • 1朱喜玲,陈金钟.阿托伐他汀对急性脑梗死患者血浆一氧化氮及血小板α颗粒膜蛋白水平的影响[J].中国基层医药,2006,13(7):1071-1072. 被引量:21
  • 2中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5220
  • 3Tanaka A,Kawarabayashi T,Nishibori Y,et al. No-reflow phenomenon and lesion morphology in patients with acute myocardial infarction. Circulation, 2002,105 ( 18 ) : 2148-2152.
  • 4Brosh D,Assali AR,Mager A,et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol, 2007,99 (4):442-445.
  • 5Kloner RA. Does reperfusion injury exist in humans? J Am CoilCardiol, 2003, 21 (2) : 537-545.
  • 6Brener SJ,EUis SG,Schneider J,et al. Frequency and long-term impact of myonecresiS after coronary stenting. Eur Heart J, 2002,23 ( 11 ) : 869-876.
  • 7Nallamothu BK, Bates ER. Periprocedural myocardial infarction and mortality: causality versus association. J Am Coil Cardiol,2003,42 ( 8 ) : 1412-1414.
  • 8Patti G,Pasceri V,Colonna G,et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coil Cardiol,2007, 49 (12) : 1272-1278.
  • 9Chyrchel M,Rakowski T,Rzeszutko L,et al. Effects of high-dase statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome. Kardiol Pol, 2006,64( 12): 1357-1362.
  • 10Di Sciascio G,Patti G,Pasceri V,et al. Efficacy of atorvastatinreload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDARECAPTURE (Atervastatin for Reduction of Myocardial Damage During Angioplasty) Randamized Trial. J Am Coil Cardiol, 2009,54(6) : 558-565.

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部